
No image available
Explore Your Options| Other Products |LAGEVRIO Molnupiravir 200mg Capsule for COVID-19 Treatment
USD 292.54
Other Products / General Merchandise / Other Products
Molnupiravir 200mg CapsuleMolnupiravir 200mg Capsule is an experimental antiviral medication authorized for emergency use in the treatment of mild-to-moderate COVID-19. It is designed for adults at high risk for progression to severe COVID-19, including hospitalization or death. This medication is taken orally and is most effective when administered within five days of symptom onset.Key Features
Authorized for emergency use by the FDA
Reduces risk of hospitalization and death by half in clinical trials
Administered as 800mg (four 200mg capsules) every 12 hours for 5 days
ApplicationUsed for treating mild-to-moderate COVID-19 in adults at high risk of severe outcomes.Typical UserAdults diagnosed with COVID-19 who are at risk of severe symptoms.About the BrandDeveloped by Merck, a leader in pharmaceutical innovation, Molnupiravir represents a significant advancement in COVID-19 treatment options.
Brand:MerckCategory:AntiviralsSKU:PHA19034Tags:Antiviral, COVID19 Treatment, Emergency Use Authorization, EUA, mcenter, Molnupiravir, Pharma
View productAuthorized for emergency use by the FDA
Reduces risk of hospitalization and death by half in clinical trials
Administered as 800mg (four 200mg capsules) every 12 hours for 5 days
ApplicationUsed for treating mild-to-moderate COVID-19 in adults at high risk of severe outcomes.Typical UserAdults diagnosed with COVID-19 who are at risk of severe symptoms.About the BrandDeveloped by Merck, a leader in pharmaceutical innovation, Molnupiravir represents a significant advancement in COVID-19 treatment options.
Brand:MerckCategory:AntiviralsSKU:PHA19034Tags:Antiviral, COVID19 Treatment, Emergency Use Authorization, EUA, mcenter, Molnupiravir, Pharma
Product details
Molnupiravir 200mg CapsuleMolnupiravir 200mg Capsule is an experimental antiviral medication authorized for emergency use in the treatment of mild-to-moderate COVID-19. It is designed for adults at high risk for progression to severe COVID-19, including hospitalization or death. This medication is taken orally and is most effective when administered within five days of symptom onset.Key Features
Authorized for emergency use by the FDA
Reduces risk of hospitalization and death by half in clinical trials
Administered as 800mg (four 200mg capsules) every 12 hours for 5 days
ApplicationUsed for treating mild-to-moderate COVID-19 in adults at high risk of severe outcomes.Typical UserAdults diagnosed with COVID-19 who are at risk of severe symptoms.About the BrandDeveloped by Merck, a leader in pharmaceutical innovation, Molnupiravir represents a significant advancement in COVID-19 treatment options.
Brand:MerckCategory:AntiviralsSKU:PHA19034Tags:Antiviral, COVID19 Treatment, Emergency Use Authorization, EUA, mcenter, Molnupiravir, Pharma
Authorized for emergency use by the FDA
Reduces risk of hospitalization and death by half in clinical trials
Administered as 800mg (four 200mg capsules) every 12 hours for 5 days
ApplicationUsed for treating mild-to-moderate COVID-19 in adults at high risk of severe outcomes.Typical UserAdults diagnosed with COVID-19 who are at risk of severe symptoms.About the BrandDeveloped by Merck, a leader in pharmaceutical innovation, Molnupiravir represents a significant advancement in COVID-19 treatment options.
Brand:MerckCategory:AntiviralsSKU:PHA19034Tags:Antiviral, COVID19 Treatment, Emergency Use Authorization, EUA, mcenter, Molnupiravir, Pharma
Product information
COL-2794860e30e88b4b6c0954c1ee3d05e19b5c67e0
Other Products / General Merchandise / Other Products
Other Products / General Merchandise / Other Products



















